A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study

JOURNAL OF THE NEUROLOGICAL SCIENCES

卷:364

Article

Montanari, Enrico¹  Rottoli, Mariarosa²  Maimone, Davide³  Confalonieri, Paolo⁴  Plewnia, Katrin⁵  Frigo, Maura⁶  Francia, Ada⁷  Pala, Antonello⁸  Losignore, Nunzia Alessandra⁹  Ragonese, Paolo¹⁰  Veneziano, Antonella¹¹ 

[1] Osped Fidenza, Azienda USL Parma, Via Don Enrico Tincati 5, I-43036 Fidenza, Italy

[2] Osped Papa Giovanni XXIII, Ctr Sclerosi Multipla, Bergamo, Italy

[3] Azienda Osped Garibaldi, UO Neurol, Ctr Sclerosi Multipla, Catania, Italy

[4] Fdn Ist Neurol Carlo Besta, UO Neurol 4, Ctr Sclerosi Multipla, Milan, Italy

[5] Osped Misericordia Grosseto, Grosseto, Italy

[6] Osped San Gerardo, Clin Neurol, Monza, Italy

[7] Azienda Policlin Umberto I, Ctr Sclerosi Multipla, Rome, Italy

[8] Presidio Osped A Segni, UO Neurol Osped, Ozieri, Italy

[9] Presidio Osped Dimiccoli, UO Neurol, Barletta, Italy

[10] Univ Palermo, Dept Expt Biomed & Clin Neurosci, Palermo, Italy

[11] Teva Italia, Dept Med, Milan, Italy

关键词: Multiple sclerosis;    Disease-modifying treatment;    Emotional burden;    Anxiety;    Depression;   

DOI  :  10.1016/j.jns.2016.02.047

来源: Elsevier

【 摘 要 】

Introduction: Depression and anxiety are common among patients with multiple sclerosis (MS) and are frequently present at the time of MS diagnosis. Methods: POSIDONIA was a 12-month, observational, prospective study conducted in Italy to evaluate the impact of disease-modifying treatment (DMT) on emotional burden in patients with recently-diagnosed MS. The Hospital Anxiety and Depression Scale (HADS), specifically HADS anxiety (HADS-A) and depression (HADS-D) sub scale scores, the Short-Form 36 Health Survey (SF-36) and the Impact of Event Scale - Revised (IES-R) were used to measure patient-reported outcomes. The Hamilton Depression Rating Scale (HORS), HDRS-17, was used as a measure of healthcare provider-reported outcomes. The primary study outcome was change from baseline in feelings of anxiety and depression over 12 months (via HADS). Results: Of 250 enrolled patients, 222 (88.8%) completed the study. At baseline, mean HADS total, HADS-A and HADS-D subscale scores were within the normal range. There were no significant changes over time in mean HADS total and HADS-A and HADS-D subscale scores, although the subgroup of patients with baseline scores indicative of anxiety or depression tended to improve over time. Both the HDRS and IES-R total scores improved over time, but there were no statistically significant changes in SF-36. Conclusion: In the patient population of the POSIDONIA study depression and anxiety were present in a minority of patients thus not allowing to detect the impact of starting DMT. However DMT appears to have a positive effect ;in patients with measurable anxiety or depression at baseline. (C) 2016 Published by Elsevier B.V.

【 授权许可】

Free